Tenaya Therapeutics (TNYA) to Release Quarterly Earnings on Monday

Tenaya Therapeutics (NASDAQ:TNYA) is projected to announce its earnings results before the market opens on Monday, March 17th. Analysts expect the company to announce earnings of ($0.32) per share for the quarter.

Tenaya Therapeutics Trading Down 3.2 %

Shares of TNYA opened at $0.46 on Monday. The firm’s 50-day moving average is $1.14 and its two-hundred day moving average is $1.88. Tenaya Therapeutics has a twelve month low of $0.39 and a twelve month high of $6.47. The firm has a market capitalization of $36.05 million, a P/E ratio of -0.32 and a beta of 2.83.

Analysts Set New Price Targets

Several research analysts have weighed in on TNYA shares. Chardan Capital restated a “buy” rating and set a $18.00 target price on shares of Tenaya Therapeutics in a research report on Wednesday, December 18th. HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Tenaya Therapeutics in a research report on Monday, February 3rd. Six research analysts have rated the stock with a buy rating, According to MarketBeat, Tenaya Therapeutics presently has an average rating of “Buy” and a consensus price target of $17.33.

Insider Activity

In other news, major shareholder Group Gp Lp Column III acquired 35,714,284 shares of Tenaya Therapeutics stock in a transaction that occurred on Wednesday, March 5th. The shares were acquired at an average price of $0.70 per share, with a total value of $24,999,998.80. Following the completion of the purchase, the insider now owns 49,313,559 shares of the company’s stock, valued at approximately $34,519,491.30. This represents a 262.62 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 32.76% of the company’s stock.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.